Rising from USD 2.5 Billion in 2022 to USD 7.8 Billion by 2032, the global clostridium diagnostics market is projected to exhibit a CAGR of 12.2% during the forecast period. From 2015 to 2021, the market displayed a CAGR of 13.6%. The growth of the market can be attributed to the rising prevalence of clostridium-related diseases and the increasing campaigns to educate individuals regarding the condition.
| Report Attribute | Key Statistics |
|---|---|
| Clostridium Diagnostics Market Size (2022) | USD 2.5 Billion |
| Clostridium Diagnostics Market Revenue Forecast (2032) | USD 7.8 Billion |
| Clostridium Diagnostics Market Growth Rate (2022 to 2032) | 12.2% |
As per the Centres for Disease Control and Prevention, Clostridium perfringens bacteria are one of the most common causes of foodborne illness (food poisoning). CDC estimates that these bacteria cause about 1 million illnesses in the States every year.
Such a significant number is expected to boost demand for an efficient clostridium diagnostics method. Other factors responsible for the market growth include changing lifestyles, developing healthcare infrastructure, and technological development such as AI and automation.
The high fatality rate of clostridium diseases, growing demand for animal-based products, and growing usage of animals in agriculture are expected to benefit the industry in the forecast period. As per the United States Department of Agriculture (USDA), the population of cattle in the USA in 2016, was 92 million and a significant population was susceptible to clostridium conditions. Such factors are likely to benefit the market in the forecast period.
The growing focus of players to offer vaccines for the fatal situation is predicted to augment the market size in the forecast period. For instance, in February 2019, Merck Animal Health and Rapid Genomics signed an agreement for vaccine verification, where Merck has exclusive rights to Rapid Genomics’ vaccination verification tool, Viral Flex-Seq.
Key companies in the market are taking several initiatives to conduct clinical trials for the development of the clostridium vaccine. For instance, in January 2017, Pfizer announced a phase II study of investigational Clostridium difficile vaccine candidate: PF-06425090; for the prevention of C. difficile infection.
The randomized Phase II study was conducted to examine the safety, immunogenicity, and tolerability of the vaccine in healthy adults 65 to 85 years of age. Pfizer initiated a phase III study in March 2017, with 16,000 participants. Attributed to such factors, the market is projected to flourish in the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Ongoing Partnerships among Players and Launch of new Vaccines to Spike the Market Growth Graph Notably
Growing expenditure on healthcare infrastructure is expected to have played a significant role in developing the market during the timeframe. As per the analysis, from 2015 to 2021, the market is projected to display a CAGR of 13.6%. Initiatives by players in the market are expected to have strengthened the industry growth during the aforementioned time period.
For instance, in August 2016, Boehringer Ingelheim Vetmedica, Inc. launched the Alpha-7 vaccine, the only first-of-a-kind vaccine, single-dose vaccination offering a 7-way defense against clostridium diseases.
Other factors contributing to the market growth include technological development in diagnostic equipment and growing awareness about clostridium-related disorders. Owing to the aforementioned factors, the market is anticipated to have developed significantly during the time period from 2015 to 2021.
During the forecast period from 2022 to 2032, the market is expected to display a CAGR of 12.2%. The growth of the market can be attributed to the growing focus of players to expand their footprint in the industry. For instance, in March 2021, Peggy Lillis Foundation for Clostridium difficile infections announced a partnership with Ferring Pharmaceutical through a new sponsorship to assist new and existing patient advocacy initiatives.
The sponsorship focuses on supporting the organization’s National C. doff Adovacy summit, 2021 FIGHT C.Diff Gala. Attributed to such factors, the global clostridium diagnostics market is projected to develop significantly during the forecast period from 2022 to 2032.
Growing Launch of New Vaccines for Clostridium Condition to Boost the Market
Players in the market are taking various efforts to offer effective vaccines against the deadly Clostridium condition, which is expected to benefit the industry in the forecast period. Growing cases of the condition among animals have encouraged players in the market to launch new vaccines.
For instance, in August 2021, Huvepharma Canada Corportation Inc. launched a new vaccine that has been shown to be effective against necrotic enteritis (NE) due to Clostridium perfringens Type A in broiler chickens.
Other factors contributing to the market growth include increasing awareness about the condition, changing lifestyles, and the development of healthcare infrastructure, among others. Such factors are expected to drive the global clostridium diagnostics market during the forecast period.
Principal Consultant
Lack of Awareness and Resources in Developing Countries to Hamper the Market Growth
Scarcity of resources and lack of awareness in developing countries is expected to be the most significant factor impeding market growth during the forecast period. Further, the high costs involved in R&D and vaccine manufacturing is projected to be another potential challenge to the market in the forecast period.
Launch of Awareness Campaigns in the States to Augment the Market Size of the USA
As per the analysis, the USA is anticipated to secure a market value worth USD 2.7 Billion during the forecast period. From 2022 to 2032, the country is projected to display a CAGR of 11.8%, while it was 13.3% from 2015 to 2021.
The growth of the USA market can be attributed to the growing awareness among people owing to the rising launch of campaigns by various bodies. For instance, the “See C. diff” campaign, launched by Peggy Lillis Foundation in December 2020, attained its objective by reaching more than 250,000 Americans.
The organization launched the “See C. diff” to commemorate C.diff Awareness Month in 2019, and reached about 80,000 people. Attributed to such efforts, the market in the USA is projected to flourish significantly in the coming time.
Implementation of Favorable Initiatives to Support the Market in Japan
As per the analysis, the market in Japan is projected to display a CAGR of 11.1% during the forecast period from 2022 to 2032. The market value is estimated at USD 464 Million by 2032. From 2015 to 2021, the country experienced a CAGR of 12.4%.
The growth of the Japanese market can be attributed to the implementation of favorable initiatives. For instance, in March 2022, Japan launched a new center, with a budget of USD 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases.
SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Due to such factors, the market in Japan is expected to experience various opportunities for expansion in the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Growing Adoption of Antibiotics for the Treatment of Infection to Develop the Segmental Growth
As per the analysis, by technology, the global clostridium diagnostics market is expected to be dominated by the immunoassays segment. The segment is anticipated to display a CAGR of 11.7% during the assessment period from 2022 to 2032.
The development of the segment can be attributed to the increasing adoption of antibiotics for infection treatment. Also, development in drug design and availability of higher antibiotics, and growing awareness about the disease are projected to strengthen the segmental growth in the forecast period.
Growing Prevalence of Clostridium-related Ailments to Boost the Segmental Growth
According to the analysis, the clostridium difficile segment is anticipated to dominate the global clostridium diagnostics market during the forecast period. From 2022 to 2032, the segment is projected to display a CAGR of 11.6%.
The development of the segment can be attributed to the growing prevalence of clostridium-related diseases and expanding geriatric population. Also, developing healthcare infrastructure and technical development are projected to be other salient factors driving the growth of the segment in the forecast period.
Acurx Pharmaceuticals, Cubist Pharmaceuticals, Endo Aesthetics, Avisa Pharma, and MGB Bio Pharma, among others, are anticipated to play a significant role in developing the market during the forecast period. Emerging entities are taking several initiatives that are likely to benefit the industry during the forecast period.
Key players in the global clostridium diagnostics market include Abbott Laboratories, F. Hoffmann-LA ROCHE AG, Siemens AG, Becton Dickinson and Company, and Beckman Coulter, INC.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 12.2% from 2022 to 2032 |
| Market Value in 2022 | USD 2.5 Billion |
| Market Value in 2032 | USD 7.8 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Technology, Product, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, France, UK, Italy, BENELUX, Nordics, China, Japan, South Korea, GCC, South Africa, Turkey |
| Key Companies Profiled | Abbott Laboratories; F. Hoffmann La-Roche AG; Siemens AG; Becton, Dickinson & Company; Beckman Coulter Inc.; Sysmex India Pvt. Ltd.; Thermo Fisher Scientific Inc.; Fujirebio US Inc.; BioMerieux S.A; Diazyme Laboratories Inc. |
| Customization | Available Upon Request |
The global clostridium diagnostics market is expected to display a CAGR of 12.2% during the forecast period.
The clostridium diagnostics market is anticipated to secure a market value worth USD 7.8 Billion by 2032.
Abbott Laboratories, F. Hoffmann-LA ROCHE AG, and Siemens AG are some of the eminent players in the global clostridium diagnostics market
The USA is projected to dominate the clostridium diagnostics market with a market value worth USD 2.7 Billion by 2032.
Immunoassays technology segment is projected to dominate the clostridium diagnostics market with a CAGR of 11.7% from 2022 to 2032
The UK Clostridium Diagnostics market is anticipated to secure USD 330 Million by 2032
1. Executive Summary 2. Market Overview 3. Market Risks and Trends Assessment 4. Market Background 5. Key Success Factors 6. Global Market Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032 7. Global Market Value Analysis 2015 to 2021 and Forecast, 2022 to 2032 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Technology 8.1. IMMUNOASSAYS 8.2. MOLECULAR DIAGNOSTICS 9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product 9.1. CLOSTRIDIUM DIFFICILE 9.2. CLOSTRIDIUM PERFRINGENS 9.3. CLOSTRIDIUM BOTULINUM 9.4. CLOSTRIDIUM TETANI 9.5. CLOSTRIDIUM SORDELLII 10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By End to user 10.1. HOSPITALS 10.2. GOVERNMENT DIAGNOSTIC LABORATORIES 10.3. INDEPENDENT LABORATORIES 11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. Asia Pacific 11.5. Middle East and Africa (MEA) 12. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032 13. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032 14. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032 15. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032 16. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032 17. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2032 18. Market Structure Analysis 19. Competition Analysis 19.1. ABBOTT LABORATORIES 19.2. F. HOFFMANN to LA ROCHE AG 19.3. SIEMENS AG 19.4. BECTON, DICKINSON AND COMPANY 19.5. BECKMAN COULTER, INC. 19.6. SYSMEX INDIA PVT. LTD. 19.7. THERMO FISHER SCIENTIFIC INC. 19.8. FUJIREBIO US, INC. 19.9. BIOMÉRIEUX SA 19.10. DIAZYME LABORATORIES, INC. 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Clostridium Diagnostics Market
